Lon­don's bio­phar­ma-fo­cused GHO Cap­i­tal Part­ners claims close of largest-ever Eu­ro­pean fund

Three years af­ter clos­ing out its first €660 mil­lion ($730.5 mil­lion) pri­vate eq­ui­ty fund, Lon­don-based GHO Cap­i­tal Part­ners has sealed a mam­moth $1 bil­lion-plus sec­ond fund, a feat it has claimed is the biggest-ever fo­cused on Eu­ro­pean health­care.

The in­vest­ment firm has al­ready in­ject­ed cap­i­tal in­to ac­tive phar­ma­ceu­ti­cal in­gre­di­ent man­u­fac­tur­er Ster­ling Phar­ma So­lu­tions and bio­an­a­lyt­i­cal test­ing com­pa­ny BioAg­i­lytix in the first quar­ter of 2019. GHO’s Fund II will in­vest in the out­sourced ser­vices, phar­ma and medtech sec­tors, the com­pa­ny said on Wednes­day.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters